BioMarin Pharmaceutical Inc
Open
SectorGezondheidszorg
55.92 -0.07
Overzicht
Wijziging aandelenprijs
24u
Min
55.28
Max
56.3
Inkomsten | -34M 106M |
|---|---|
Verkoop | -108M 766M |
K/W Sectorgemiddelde | 40.684 49.052 |
EPS | 0.76 |
Winstmarge | 13.773 |
Werknemers | 3,221 |
EBITDA | 177M 173M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +55.5% upside |
Volgende Winsten | 3 aug 2026 |
|---|
Marktkapitalisatie | 531M 11B |
|---|---|
Vorige openingsprijs | 55.99 |
Vorige sluitingsprijs | 55.92 |
Nieuwssentiment
By Acuity
50%
50%
146 / 342 Rangschikking in Healthcare
BioMarin Pharmaceutical Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.